https://www.selleckchem.com/pr....oducts/stemRegenin-1
orting long-term symptoms and whether higher symptoms of diarrhea in early illness presages deterioration. Real-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study evaluated treatment and clinical outcomes of immunocompromised patients receiving C/T for multidrug-resistant (MDR) . This was a 14-center retrospective cohort study of adult immunocompromised inpatients treated for ≥24 hours with C/T for MDR infections. Patients were defined as immunocompromised
Like
Comment
Share
